Structure-based drug design, synthesis, In vitro, and In vivo biological evaluation of indole-based biomimetic analogs targeting estrogen receptor-α inhibition

Moataz S. Hendy, Aya A. Ali, Lubna Ahmed, Reham Hossam, Alaa Mostafa, Mohamed M. Elmazar, Bassem H. Naguib, Yasmeen M. Attia, Mahmoud Salama Ahmed

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Offering novel scaffolds targeting estrogen receptor creates huge necessity to overcome the evolving resistance developed by tumors. Structure-based drug design coupled with ring opening strategy of the steroids skeleton revealed the potential of indole-based analogs to be synthesized targeting the ligand binding domain of estrogen receptor-α. In vitro studies revealed the potential of the total sub-classes of the synthesized analogs to show anti-proliferative activity against estrogen receptor-dependent cancer cell lines at IC50 ranging from 28.23 to 57.13 μM. This was further validated by evaluating the potential of the synthesized analogs to compete along with estradiol via ER-α ELISA assay to show inhibitory profile at IC50 ranging from 1.76 to 204.75 nM. Two analogs (YMA-005 and YMA-006) showed significant reduction in tumor size at two dose levels with extensive degeneration and necrosis. Both YMA-005 and YMA-006 showed in-situ reduction of ER-α Immunohistochemical expression at both dose levels. Ultimately, novel analogs of indole-based biomimetic of estrone scaffolds were offered as estrogen receptor-α inhibitors.

Original languageEnglish (US)
Pages (from-to)281-290
Number of pages10
JournalEuropean Journal of Medicinal Chemistry
Volume166
DOIs
StatePublished - Mar 15 2019

Fingerprint

Biomimetics
Drug Design
Estrogen Receptors
Scaffolds (biology)
Pharmaceutical Preparations
Inhibitory Concentration 50
Tumors
Neoplasms
Estrone
Skeleton
Estradiol
Assays
Necrosis
Enzyme-Linked Immunosorbent Assay
Steroids
Cells
Ligands
Cell Line
In Vitro Techniques
indole

Keywords

  • Biologically inspired organic synthesis
  • Breast cancer
  • Estrogen receptor-α
  • Indole

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Structure-based drug design, synthesis, In vitro, and In vivo biological evaluation of indole-based biomimetic analogs targeting estrogen receptor-α inhibition. / Hendy, Moataz S.; Ali, Aya A.; Ahmed, Lubna; Hossam, Reham; Mostafa, Alaa; Elmazar, Mohamed M.; Naguib, Bassem H.; Attia, Yasmeen M.; Ahmed, Mahmoud Salama.

In: European Journal of Medicinal Chemistry, Vol. 166, 15.03.2019, p. 281-290.

Research output: Contribution to journalArticle

Hendy, Moataz S. ; Ali, Aya A. ; Ahmed, Lubna ; Hossam, Reham ; Mostafa, Alaa ; Elmazar, Mohamed M. ; Naguib, Bassem H. ; Attia, Yasmeen M. ; Ahmed, Mahmoud Salama. / Structure-based drug design, synthesis, In vitro, and In vivo biological evaluation of indole-based biomimetic analogs targeting estrogen receptor-α inhibition. In: European Journal of Medicinal Chemistry. 2019 ; Vol. 166. pp. 281-290.
@article{f4d4a13173744e48bd4ac6382fc69f66,
title = "Structure-based drug design, synthesis, In vitro, and In vivo biological evaluation of indole-based biomimetic analogs targeting estrogen receptor-α inhibition",
abstract = "Offering novel scaffolds targeting estrogen receptor creates huge necessity to overcome the evolving resistance developed by tumors. Structure-based drug design coupled with ring opening strategy of the steroids skeleton revealed the potential of indole-based analogs to be synthesized targeting the ligand binding domain of estrogen receptor-α. In vitro studies revealed the potential of the total sub-classes of the synthesized analogs to show anti-proliferative activity against estrogen receptor-dependent cancer cell lines at IC50 ranging from 28.23 to 57.13 μM. This was further validated by evaluating the potential of the synthesized analogs to compete along with estradiol via ER-α ELISA assay to show inhibitory profile at IC50 ranging from 1.76 to 204.75 nM. Two analogs (YMA-005 and YMA-006) showed significant reduction in tumor size at two dose levels with extensive degeneration and necrosis. Both YMA-005 and YMA-006 showed in-situ reduction of ER-α Immunohistochemical expression at both dose levels. Ultimately, novel analogs of indole-based biomimetic of estrone scaffolds were offered as estrogen receptor-α inhibitors.",
keywords = "Biologically inspired organic synthesis, Breast cancer, Estrogen receptor-α, Indole",
author = "Hendy, {Moataz S.} and Ali, {Aya A.} and Lubna Ahmed and Reham Hossam and Alaa Mostafa and Elmazar, {Mohamed M.} and Naguib, {Bassem H.} and Attia, {Yasmeen M.} and Ahmed, {Mahmoud Salama}",
year = "2019",
month = "3",
day = "15",
doi = "10.1016/j.ejmech.2019.01.068",
language = "English (US)",
volume = "166",
pages = "281--290",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Structure-based drug design, synthesis, In vitro, and In vivo biological evaluation of indole-based biomimetic analogs targeting estrogen receptor-α inhibition

AU - Hendy, Moataz S.

AU - Ali, Aya A.

AU - Ahmed, Lubna

AU - Hossam, Reham

AU - Mostafa, Alaa

AU - Elmazar, Mohamed M.

AU - Naguib, Bassem H.

AU - Attia, Yasmeen M.

AU - Ahmed, Mahmoud Salama

PY - 2019/3/15

Y1 - 2019/3/15

N2 - Offering novel scaffolds targeting estrogen receptor creates huge necessity to overcome the evolving resistance developed by tumors. Structure-based drug design coupled with ring opening strategy of the steroids skeleton revealed the potential of indole-based analogs to be synthesized targeting the ligand binding domain of estrogen receptor-α. In vitro studies revealed the potential of the total sub-classes of the synthesized analogs to show anti-proliferative activity against estrogen receptor-dependent cancer cell lines at IC50 ranging from 28.23 to 57.13 μM. This was further validated by evaluating the potential of the synthesized analogs to compete along with estradiol via ER-α ELISA assay to show inhibitory profile at IC50 ranging from 1.76 to 204.75 nM. Two analogs (YMA-005 and YMA-006) showed significant reduction in tumor size at two dose levels with extensive degeneration and necrosis. Both YMA-005 and YMA-006 showed in-situ reduction of ER-α Immunohistochemical expression at both dose levels. Ultimately, novel analogs of indole-based biomimetic of estrone scaffolds were offered as estrogen receptor-α inhibitors.

AB - Offering novel scaffolds targeting estrogen receptor creates huge necessity to overcome the evolving resistance developed by tumors. Structure-based drug design coupled with ring opening strategy of the steroids skeleton revealed the potential of indole-based analogs to be synthesized targeting the ligand binding domain of estrogen receptor-α. In vitro studies revealed the potential of the total sub-classes of the synthesized analogs to show anti-proliferative activity against estrogen receptor-dependent cancer cell lines at IC50 ranging from 28.23 to 57.13 μM. This was further validated by evaluating the potential of the synthesized analogs to compete along with estradiol via ER-α ELISA assay to show inhibitory profile at IC50 ranging from 1.76 to 204.75 nM. Two analogs (YMA-005 and YMA-006) showed significant reduction in tumor size at two dose levels with extensive degeneration and necrosis. Both YMA-005 and YMA-006 showed in-situ reduction of ER-α Immunohistochemical expression at both dose levels. Ultimately, novel analogs of indole-based biomimetic of estrone scaffolds were offered as estrogen receptor-α inhibitors.

KW - Biologically inspired organic synthesis

KW - Breast cancer

KW - Estrogen receptor-α

KW - Indole

UR - http://www.scopus.com/inward/record.url?scp=85060948583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060948583&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2019.01.068

DO - 10.1016/j.ejmech.2019.01.068

M3 - Article

C2 - 30731397

AN - SCOPUS:85060948583

VL - 166

SP - 281

EP - 290

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -